Literature DB >> 16570136

Signal transduction underlying the vascular effects of sphingosine 1-phosphate and sphingosylphosphorylcholine.

Denise G Hemmings1.   

Abstract

Two related lysosphingolipids, sphingosine 1-phosphate (S1P) and sphingosylphosphorylcholine (SPC) mediate diverse cellular responses through signals transduced by either activation of G-protein coupled receptors or possibly by acting intracellularly. Vascular responses to S1P and SPC measured both in vivo and in dissected vessels show predominantly vasoconstriction with some evidence for vasodilation. Although stimulation with S1P or SPC generally leads to similar vascular responses, the signalling pathways stimulated to produce these responses are often distinct. Nevertheless, mobilization of Ca2+ from intracellular stores and influx of extracellular Ca2+, which both increase [Ca2+]i, occur in response to S1P and SPC. Both mobilization of Ca2+ from intracellular stores and influx of extracellular Ca2+ occur in response to S1P and SPC. As well, both S1P and SPC induce Ca2+-sensitization in vascular smooth muscle which is mediated through Rho kinase activation. In the endothelium, S1P and SPC stimulate the production of the vasodilator, nitric oxide through activation of endothelial nitric oxide synthase. This activation occurs through phosphorylation by Akt and through binding of Ca2+-calmodulin upon increased [Ca2+]i. These lysosphingolipids also activate cyclooxygenase-2 which produces prostaglandins with both vasoconstrictor and vasodilator properties. A balance between the signals inducing vasodilation versus the signals inducing vasoconstriction will determine the vascular outcome. Thus, perturbations in S1P and SPC concentrations, relative expression of receptors or downstream signalling pathways may provide a mechanism for pathophysiological conditions such as hypertension. Given this background, recent studies examining a potential role for S1P and SPC in hypertension and vascular dysfunction in aging are discussed.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16570136     DOI: 10.1007/s00210-006-0046-5

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  109 in total

Review 1.  Signaling of sphingosine-1-phosphate via the S1P/EDG-family of G-protein-coupled receptors.

Authors:  Michael J Kluk; Timothy Hla
Journal:  Biochim Biophys Acta       Date:  2002-05-23

2.  Sphingosine 1-phosphate and control of vascular tone.

Authors:  Ana Paula V Dantas; Junsuke Igarashi; Thomas Michel
Journal:  Am J Physiol Heart Circ Physiol       Date:  2003-06       Impact factor: 4.733

3.  Immunomodulator FTY720 Induces eNOS-dependent arterial vasodilatation via the lysophospholipid receptor S1P3.

Authors:  Markus Tölle; Bodo Levkau; Petra Keul; Volker Brinkmann; Günter Giebing; Gilbert Schönfelder; Michael Schäfers; Karin von Wnuck Lipinski; Joachim Jankowski; Vera Jankowski; Jerold Chun; Walter Zidek; Markus Van der Giet
Journal:  Circ Res       Date:  2005-03-31       Impact factor: 17.367

4.  Inhibition of autotaxin by lysophosphatidic acid and sphingosine 1-phosphate.

Authors:  Laurens A van Meeteren; Paula Ruurs; Evangelos Christodoulou; James W Goding; Hideo Takakusa; Kazuya Kikuchi; Anastassis Perrakis; Tetsuo Nagano; Wouter H Moolenaar
Journal:  J Biol Chem       Date:  2005-03-15       Impact factor: 5.157

5.  Sphingosylphosphocholine is a naturally occurring lipid mediator in blood plasma: a possible role in regulating cardiac function via sphingolipid receptors.

Authors:  K Liliom; G Sun; M Bünemann; T Virág; N Nusser; D L Baker; D A Wang; M J Fabian; B Brandts; K Bender; A Eickel; K U Malik; D D Miller; D M Desiderio; G Tigyi; L Pott
Journal:  Biochem J       Date:  2001-04-01       Impact factor: 3.857

6.  Sphingosylphosphorylcholine induces Ca(2+)-sensitization of vascular smooth muscle contraction: possible involvement of rho-kinase.

Authors:  N Todoroki-Ikeda; Y Mizukami; K Mogami; T Kusuda; K Yamamoto; T Miyake; M Sato; S Suzuki; H Yamagata; Y Hokazono; S Kobayashi
Journal:  FEBS Lett       Date:  2000-09-29       Impact factor: 4.124

7.  Nitric oxide-induced decrease in calcium sensitivity of resistance arteries is attributable to activation of the myosin light chain phosphatase and antagonized by the RhoA/Rho kinase pathway.

Authors:  Steffen-Sebastian Bolz; Lukas Vogel; Daniel Sollinger; Roland Derwand; Cor de Wit; Gervaise Loirand; Ulrich Pohl
Journal:  Circulation       Date:  2003-06-09       Impact factor: 29.690

8.  Transactivation of vascular endothelial growth factor (VEGF) receptor Flk-1/KDR is involved in sphingosine 1-phosphate-stimulated phosphorylation of Akt and endothelial nitric-oxide synthase (eNOS).

Authors:  Tatsuo Tanimoto; Zheng-Gen Jin; Bradford C Berk
Journal:  J Biol Chem       Date:  2002-09-10       Impact factor: 5.157

9.  Ca2+ signaling induced by sphingosylphosphorylcholine and sphingosine 1-phosphate via distinct mechanisms in rat glomerular mesangial cells.

Authors:  P F Chen; T Y Chin; S H Chueh
Journal:  Kidney Int       Date:  1998-11       Impact factor: 10.612

10.  Predicting obstructive coronary artery disease with serum sphingosine-1-phosphate.

Authors:  Douglas H Deutschman; Jeffrey S Carstens; Robert L Klepper; Wyatt S Smith; M Trevor Page; Thomas R Young; Lisa A Gleason; Nobuko Nakajima; Roger A Sabbadini
Journal:  Am Heart J       Date:  2003-07       Impact factor: 4.749

View more
  21 in total

Review 1.  Regulation and functional roles of sphingosine kinases.

Authors:  Regina Alemany; Chris J van Koppen; Kerstin Danneberg; Michael Ter Braak; Dagmar Meyer Zu Heringdorf
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-01-23       Impact factor: 3.000

2.  Pericyte chemomechanics and the angiogenic switch: insights into the pathogenesis of proliferative diabetic retinopathy?

Authors:  Jennifer T Durham; Brian M Dulmovits; Stephen M Cronk; Anthony R Sheets; Ira M Herman
Journal:  Invest Ophthalmol Vis Sci       Date:  2015-06       Impact factor: 4.799

Review 3.  Sphingosine-1-phosphate signaling in blood pressure regulation.

Authors:  Suttira Intapad
Journal:  Am J Physiol Renal Physiol       Date:  2019-08-07

4.  Protection against myocardial ischemia/reperfusion injury by short-term diabetes: enhancement of VEGF formation, capillary density, and activation of cell survival signaling.

Authors:  Guochuan Ma; Mohamed Al-Shabrawey; John A Johnson; Rahul Datar; Huda E Tawfik; Dehuang Guo; Ruth B Caldwell; R William Caldwell
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-09-06       Impact factor: 3.000

Review 5.  Pharmacological relevance and potential of sphingosine 1-phosphate in the vascular system.

Authors:  Mirjam Schuchardt; Markus Tölle; Jasmin Prüfer; Markus van der Giet
Journal:  Br J Pharmacol       Date:  2011-07       Impact factor: 8.739

6.  Interaction between anandamide and sphingosine-1-phosphate in mediating vasorelaxation in rat coronary artery.

Authors:  K M Mair; E Robinson; K A Kane; S Pyne; R R Brett; N J Pyne; S Kennedy
Journal:  Br J Pharmacol       Date:  2010-09       Impact factor: 8.739

Review 7.  The role of sphingosine-1-phosphate in breast cancer tumor-induced lymphangiogenesis.

Authors:  Tomoyoshi Aoyagi; Masayuki Nagahashi; Akimitsu Yamada; Kazuaki Takabe
Journal:  Lymphat Res Biol       Date:  2012-09       Impact factor: 2.589

8.  Effect of sphingosine kinase 1 inhibition on blood pressure.

Authors:  Hideki Furuya; Masayuki Wada; Yoshiko Shimizu; Paulette M Yamada; Yusuf A Hannun; Lina M Obeid; Toshihiko Kawamori
Journal:  FASEB J       Date:  2012-10-29       Impact factor: 5.191

9.  Effects of sphingosine-1-phosphate on pacemaker activity of interstitial cells of Cajal from mouse small intestine.

Authors:  Young Dae Kim; Kyoung Taek Han; Jun Lee; Chan Guk Park; Man Yoo Kim; Pawan Kumar Shahi; Dong Chuan Zuo; Seok Choi; Jae Yeoul Jun
Journal:  Mol Cells       Date:  2013-01-09       Impact factor: 5.034

Review 10.  "Inside-out" signaling of sphingosine-1-phosphate: therapeutic targets.

Authors:  Kazuaki Takabe; Steven W Paugh; Sheldon Milstien; Sarah Spiegel
Journal:  Pharmacol Rev       Date:  2008-06-13       Impact factor: 25.468

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.